Lataa...
Efficacy and Safety of Low-Dose Pemafibrate Therapy for Hypertriglyceridemia in Patients with Type 2 Diabetes
INTRODUCTION: Pemafibrate is a potent selective peroxisome proliferator-activated receptor α (PPARα) modulator that may be safer than conventional PPARα agonists in the treatment of dyslipidemia. This study was designed to investigate the efficacy of low-dose pemafibrate (0.1 mg/day) therapy for hyp...
Tallennettuna:
| Julkaisussa: | JMA J |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Japan Medical Association
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8118964/ https://ncbi.nlm.nih.gov/pubmed/33997447 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.31662/jmaj.2020-0104 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|